Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

INTRODUCTION: The combination of lenvatinib plus pembrolizumab demonstrated a relevant clinical benefit in patients with endometrial carcinoma. The safety profile was consistent with the established profiles of each drug in monotherapy, with the most frequent adverse events being hypertension, an on...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorusso, Domenica, Danesi, Romano, Locati, Laura Deborah, Masi, Gianluca, De Giorgi, Ugo, Gadducci, Angiolo, Pignata, Sandro, Sabbatini, Roberto, Savarese, Antonella, Valabrega, Giorgio, Zamagni, Claudio, Colombo, Nicoletta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535356/
https://www.ncbi.nlm.nih.gov/pubmed/36212444
http://dx.doi.org/10.3389/fonc.2022.979519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535356/
https://www.ncbi.nlm.nih.gov/pubmed/36212444
http://dx.doi.org/10.3389/fonc.2022.979519

Ejemplares similares